Agenus Raises Up to $340M on Neoadjuvant MSS Colon Cancer
Agenus announced an oversubscribed private placement that could provide up to $340 million to support the registrational development of botensilimab plus balstilimab, also known as BOT/BAL, in neoadjuvant microsatellite-stable colon cancer. The financing includes…
